CoChat

Effects of the Long-Acting Human Glucagon-Like Peptide-1 Analog Liraglutide on β-Cell Function in Normal Living Conditions

Open access
Mari, Andrea, Degn, Kristine, Brock, Birgitte, Rungby, Joergen, Ferrannini, Ele, Schmitz, Ole · 2007 · Diabetes Care
Cited by 84

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

iraglutide is a long-acting glucagonlike peptide (GLP)-1 analog, which exerts its glucose-lowering action through multiple mechanisms (1).One important feature of liraglutide is its ability to enhance ␤-cell function.The effects on ␤-cell function have been demonstrated using standardized ␤-cell function tests based on intravenous glucose administration (2-4).However, these studies may not reflect the modes of action of liraglutide during normal living.To assess the effects of liraglutide on ␤-cell function in normal living, we have used a validated ␤-cell model to analyze 24-h triple-meal experiments. RESEARCH DESIGN AND METHODS-This study includes data used for a different analysis in a previous publication (3), where the experimental protocol, approved by the local ethics committee and performed in accordance with the Helsinki Declaration, was described in detail.Thirteen type 2 diabetic patients (five women and eight men) were examined.Their mean Ϯ SD age was 56.4 Ϯ 9.2 years, BMI was 31.2Ϯ 3.6 kg/m 2 , last measured A1C before inclusion was 7.3 Ϯ 0.4% (normal range Ͻ6.4%), and the duration of diabetes was 3.0 Ϯ 2.6 years.The study is a randomized, doubleblind, placebo-controlled, crossover

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc07-0310

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 84

Metadata

Authors
Mari, A., Degn, K., Brock, B., Rungby, J., Ferrannini, E., & Schmitz, O.
Venue
Diabetes Care
Published
2007-08-01
Volume
30
Issue
8
Pages
2032-2033
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2129449971
Cited by
84
References
1
FWCI
7.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.